Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Liabilities and Shareholders Equity: 2017-2025

Historic Liabilities and Shareholders Equity for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $202.9 million.

  • Puma Biotechnology's Liabilities and Shareholders Equity fell 8.09% to $202.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.3 million, marking a year-over-year decrease of 7.25%. This contributed to the annual value of $213.3 million for FY2024, which is 7.46% down from last year.
  • Latest data reveals that Puma Biotechnology reported Liabilities and Shareholders Equity of $202.9 million as of Q3 2025, which was up 4.08% from $194.9 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Liabilities and Shareholders Equity peaked at $260.0 million during Q2 2021, and registered a low of $193.7 million during Q2 2022.
  • Over the past 3 years, Puma Biotechnology's median Liabilities and Shareholders Equity value was $203.6 million (recorded in 2023), while the average stood at $207.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first rose by 14.69% in 2021, then dropped by 25.52% in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Liabilities and Shareholders Equity stood at $226.6 million in 2021, then fell by 2.00% to $222.1 million in 2022, then increased by 3.81% to $230.5 million in 2023, then fell by 7.46% to $213.3 million in 2024, then declined by 8.09% to $202.9 million in 2025.
  • Its last three reported values are $202.9 million in Q3 2025, $194.9 million for Q2 2025, and $196.2 million during Q1 2025.